Science at Sanofi

MS Pulse is a series of short, engaging reels covering different aspects of multiple sclerosis—from everyday challenges to practical insights. The series is designed to simplify complex topics and support better understanding, conversations, and care in MS.

The FLUNITY-HD Study is the largest individually randomized influenza vaccine effectiveness study and the first of its kind for an influenza vaccine.
The study demonstrates the superior benefit of HD-IIV, specifically developed for older adults, compared with SD-IIV against a wide range of hospitalization outcomes in a prespecified and powered analysis encompassing nearly half a million participants. Providing the high-quality data, this study provides further critical evidence that widespread use of HD-IIV could substantially reduce the burden of influenza on both older adults and healthcare systems globally.

HD-IIV consistently reduced severe hospitalization outcomes compared with SD-IIV regardless of prior history of CVD. Among specific CV outcomes¹, HD-IIV conferred a particularly substantial benefit against hospitalization for HF compared with SD-IIV.¹ Moreover, another prespecified analysis supports the use of HD-IIV for reducing both influenza specific and other hospitalization outcomes in older individuals both with and without preexisting ASCVD, with potentially greater absolute benefit among individuals with ASCVD. ²